Scinai Immunotherapeutics Ltd. (SCNI) Key Metrics
SCNI valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $1.0M
- Enterprise value
- $7.9M
- P/E (TTM)
- 0.0
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.7
- Price / book
- 0.2
- EV / EBITDA
- 1.1
- Dividend yield
- —
- Beta
- 2.13
SCNI key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSCNI returns How much profit the business earns on the capital it uses.
SCNI financial health Debt, liquidity and how easily interest is covered.
SCNI efficiency & capital use Working capital cycle and where the cash goes.
SCNI returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SCNI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SCNI key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $7.12 | $33.45 | $59.54 | $296.00 | $2,350.00 | $2,810.00 | $9,290.00 | $4,770.00 | $5,360.00 | $3,350.00 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −91.9% | 177.4% | — | — | — | — | — | — | −87.0% | −31.2% |
| Return on invested capital (ROIC) | −63.4% | −64.3% | −91.1% | −94.2% | −64.9% | −269.5% | — | — | — | — |
| Return on assets (ROA) | −66.3% | 31.0% | −29.2% | −19.6% | −49.8% | −5.1% | −102.3% | −90.6% | −63.5% | −25.9% |
| Return on tangible assets | −71.5% | 35.7% | −37.2% | −21.4% | −38.6% | −7.3% | −94.3% | −82.9% | −42.3% | −30.5% |
| Free cash flow margin | −461.9% | −964.6% | — | — | — | — | — | — | — | — |
| Income quality (OCF / net income) | — | −1.32 | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $2.3M | $2.1M | $20.6M | $21.5M | $29.2M | $20.9M | $38.0M | $25.2M | — | — |
| Cash & short-term investments | $1.7M | $2.0M | $4.9M | $14.1M | $17.4M | $2.9M | $21.0M | $20.3M | $20.5M | $6.6M |
| Net debt | $606,000 | $122,000 | $15.7M | $7.5M | $11.9M | $18.0M | $17.0M | $4.9M | −$20.5M | −$6.6M |
| Debt / equity | 0.28 | 0.21 | — | — | 29.77 | — | — | — | — | — |
| Debt / assets | 0.19 | 0.16 | 1.18 | 0.80 | 0.91 | 1.18 | 1.13 | 0.89 | — | — |
| Current ratio | 1.30 | 1.32 | 3.06 | 6.15 | 7.30 | 0.17 | 3.86 | 3.53 | 10.94 | 19.01 |
| Quick ratio | 1.30 | 1.32 | 3.27 | 6.51 | 7.40 | 0.36 | 3.86 | 3.53 | 10.94 | 18.87 |
| Interest coverage | -21.0 | -6.0 | -2.6 | -2.2 | -3.2 | -58.5 | -5.3 | -5.4 | -332.4 | — |
| Working capital | $469,000 | $585,000 | $3.7M | $12.0M | $15.4M | −$16.7M | $15.7M | $14.7M | $19.7M | $6.4M |
| Invested capital | $8.7M | $10.1M | $11.1M | $5.7M | $12.8M | $13.4M | −$1.8M | −$3.4M | −$4.3M | $75,789 |
| Tangible asset value | $8.1M | $10.0M | −$4.6M | −$1.8M | $982,000 | −$4.5M | −$18.8M | −$8.3M | $16.2M | $6.6M |
| Net current asset value | −$1.5M | −$1.1M | −$16.6M | −$14.5M | −$13.2M | −$18.9M | −$31.2M | −$16.1M | $14.3M | $5.6M |
| Capital allocation | ||||||||||
| Capex / revenue | 1.8% | 1.8% | — | — | — | — | — | — | — | — |
| Capex / depreciation | 0.02 | 0.01 | 1.24 | 1.49 | 0.30 | 2.52 | 4.66 | 87.75 | 10.49 | 0.03 |
| Stock-based compensation / revenue | 23.1% | 103.6% | — | — | — | — | — | — | — | — |
| R&D / revenue | 180.7% | 840.7% | — | — | — | — | — | — | — | — |
| SG&A / revenue | 192.3% | 383.9% | — | — | — | — | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | 53.6 | 161.7 | — | — | — | — | — | — | — | — |
| Days of inventory on hand | — | — | -433.7 | -356.4 | -1,003.0 | -1,991.6 | — | — | — | — |
| Days payables outstanding | 36.1 | 134.3 | 445.3 | 559.1 | 385.7 | 1,421.5 | 4,143.5 | 18,497.9 | 2,904.7 | — |
| Cash conversion cycle (days) | 17.5 | 27.4 | — | — | — | — | — | — | — | — |
| Receivables turnover | 6.81 | 2.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 10.12 | 2.72 | 0.82 | 0.65 | 0.95 | 0.26 | 0.09 | 0.02 | 0.13 | — |
| Asset turnover | 0.10 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $192,500 | $291,500 | $238,000 | $217,576 | $198,184 | $210,108 | $302,613 | $1.7M | $2.0M | $1.1M |
| Average payables | $391,500 | $455,500 | $625,500 | $857,500 | $790,094 | $2.8M | $5.2M | $3.7M | $983,238 | $208,492 |
| Average inventory | — | — | −$609,140 | −$546,564 | −$2.1M | −$3.9M | — | — | — | $51,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SCNI's annual financial statements (latest annual report filed April 1, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SCNI valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.0. Scinai Immunotherapeutics earned a return on equity of −91.9% and a return on invested capital of −63.4% in fiscal 2025. It ended the year with $2.3 million of debt and $1.7 million in cash and short-term investments, net debt of $0.6 million.
See the SCNI income statement, the SCNI chart for price history, or the SCNI stock overview for the latest quote and news.
SCNI key metrics FAQ
What is Scinai Immunotherapeutics's P/E ratio?
Scinai Immunotherapeutics's trailing P/E ratio is 0.0 based on the last twelve months of earnings (as of October 17, 2026). At the end of fiscal 2025 it was —.
What is Scinai Immunotherapeutics's return on equity?
Scinai Immunotherapeutics's return on equity (ROE) was −91.9% in fiscal 2025: net income of -$8.3 million on average shareholders' equity of $9.0 million.
What is Scinai Immunotherapeutics's ROIC?
Scinai Immunotherapeutics's return on invested capital was −63.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics had total debt of $2.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.28.
What is Scinai Immunotherapeutics's current ratio?
Scinai Immunotherapeutics's current ratio was 1.30 at the end of fiscal 2025: current assets were 1.30 times current liabilities.